<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263119</url>
  </required_header>
  <id_info>
    <org_study_id>12595</org_study_id>
    <secondary_id>H9P-EW-LNCF</secondary_id>
    <nct_id>NCT01263119</nct_id>
  </id_info>
  <brief_title>A Study of LY2216684 and Warfarin in Healthy Subjects</brief_title>
  <official_title>Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how warfarin might affect LY2216684 and how giving
      LY2216684 might affect warfarin in the body. Information about any side effects that may
      occur will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of S-warfarin, area under the concentration curve (AUC,0-∞)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of S-warfarin, maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of S-warfarin, time to concentration maximum (tmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of R-warfarin, area under the concentration curve (AUC,0-∞)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of R-warfarin, concentration maximum (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of R-warfarin, time to concentration maximum (tmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post warfarin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the INR (international normalized ratio) curve</measure>
    <time_frame>Predose, 6, 12, 24, 48, 72, 96, 120, 144 hours after warfarin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed INR response</measure>
    <time_frame>Predose, 6, 12, 24, 48, 72, 96, 120, 144 hours after warfarin administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Warfarin, LY2216684+Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 10 mg warfarin on Day 1 in period 1. Oral dose of 18 mg LY2216684 once daily (QD) on Days 1 to 12, with a single oral dose of 10 mg warfarin co-administered on Day 3 in period 2. There is a washout period of at least 14 days between dosing periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Warfarin, LY2216684+Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Warfarin, LY2216684+Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy, as determined by medical history and physical examination.

          -  Male subjects - Agree to use a reliable method of birth control during the study and
             for 1 month following the last dose of study drug.

          -  Female subjects - Are women of child-bearing potential who test negative for pregnancy
             at the time of enrollment, have used a reliable method of birth control for 6 weeks
             prior to administration of study drug, and agree to use a reliable method of birth
             control during the study and for 1 month following the last dose of study drug; or
             Women not of child-bearing potential due to surgical sterilization (hysterectomy or
             bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses
             or 6 months without menses and a follicle stimulating hormone [FSH] &gt;40 mIU/mL).

          -  Have body weight &gt;50 kg.

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator.

          -  Have venous access sufficient to allow blood sampling as per the protocol.

          -  Have normal blood pressure and pulse rate (sitting position) as determined by the
             investigator.

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures.

          -  Have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site.

          -  Are CYP2C9 extensive metabolizers as determined by genotyping assessment.

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an investigational drug or device or off-label use of a drug or device
             other than the study drug, or are concurrently enrolled in any other type of medical
             research judged not to be scientifically or medically compatible with this study.

          -  Have known allergies to LY2216684, warfarin, or related compounds.

          -  Are persons who have previously completed or withdrawn from this study or any other
             study investigating LY2216684 within 6 months prior to screening.

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study.

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data.

          -  Have a history or show evidence of significant active neuropsychiatric disease or have
             a history of suicide attempt or ideation.

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening.

          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV
             antibodies.

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody.

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen.

          -  Are women with a positive pregnancy test or women who are lactating.

          -  Intend to use over-the-counter or prescription medication (including hormonal
             contraceptives) within 14 days prior to dosing unless deemed acceptable by the
             investigator and Sponsor's medical monitor

          -  Use of any drugs or substances that are known to be substrates, inducers, or
             inhibitors of CYP2C19 or CYP2C9 within 30 days prior to dosing.

          -  Have donated blood of more than 500 mL within the last month.

          -  Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling
             to stop alcohol consumption 48 hours prior to dosing in each period and while resident
             at the CRU (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL
             of distilled spirits).

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine
             restrictions.

          -  Have used any tobacco-containing or nicotine-containing products (including but not
             limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine
             lozenges, or nicotine gum) within 6 months prior to enrollment.

          -  Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment
             and during the study.

          -  Have a documented or suspected history of glaucoma.

          -  History or presence of significant bleeding disorders that is, hematemesis, melanena,
             severe or recurrent epistaxis, hemoptysis, clinically overt hematuria or intracranial
             hemorrhage.

          -  Subjects with a history of gastrointestinal ulcers or hemorrhage.

          -  Personal or family history of coagulation or bleeding disorders or reasonable
             suspicion of vascular malformations, for example, cerebral hemorrhage, aneurysm or
             premature stroke (cerebrovascular accident &lt;65 years of age).

          -  Self-reported history of increased bleeding from trauma (for example, prolonged
             bleeding after tooth extraction).

          -  History of major surgery within 3 months of screening.

          -  Planned surgery within 14 days after the last day of dosing.

          -  INR/PT, or activated partial thromboplastin time (APTT) above the normal reference
             range at screening.

          -  Positive fecal occult blood examination at screening.

          -  Female subjects with a history of menorrhagia.

          -  Subjects determined to be unsuitable by the investigator for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 17, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

